116 related articles for article (PubMed ID: 35306157)
1. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
Tomasik B; Bieńkowski M; Jassem J
Ann Oncol; 2022 Jun; 33(6):658-659. PubMed ID: 35306157
[No Abstract] [Full Text] [Related]
2. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.
Poggio F; Tagliamento M; Ceppi M; Bruzzone M; Conte B; Fregatti P; Punie K; de Azambuja E; Del Mastro L; Lambertini M
Ann Oncol; 2022 Mar; 33(3):347-349. PubMed ID: 34861375
[No Abstract] [Full Text] [Related]
3. Role of Platinums in Triple-Negative Breast Cancer.
Lynce F; Nunes R
Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
[TBL] [Abstract][Full Text] [Related]
4. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
[No Abstract] [Full Text] [Related]
5. Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki Y; Shimomura A; Yoshimura K; Terakado H; Shimizu C
J Clin Oncol; 2021 Nov; 39(31):3521-3522. PubMed ID: 34554850
[No Abstract] [Full Text] [Related]
6. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
[TBL] [Abstract][Full Text] [Related]
7. Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Rediti M; Messina C
Breast Cancer Res Treat; 2018 Nov; 172(1):239-240. PubMed ID: 30003394
[No Abstract] [Full Text] [Related]
8. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
Dent R; Rugo HS
Lancet Oncol; 2021 Jan; 22(1):27-28. PubMed ID: 33387495
[No Abstract] [Full Text] [Related]
9. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant chemotherapy in triple-negative breast cancer: is there a role for platinum?].
Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1063. PubMed ID: 25776517
[No Abstract] [Full Text] [Related]
12. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
13. [Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer].
Hao XP; Jiang ZF
Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):101-103. PubMed ID: 33378800
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
Wang D; Feng J; Xu B
Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
[No Abstract] [Full Text] [Related]
16. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
[TBL] [Abstract][Full Text] [Related]
17. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of neoadjuvant chemotherapy combined with low-dose Apatinib in the treatment of triple negative breast cancer.
Yang JZ; Bao YF; Ci YJ; Zhu JJ
Asian J Surg; 2023 Jul; 46(7):2703-2704. PubMed ID: 36990815
[No Abstract] [Full Text] [Related]
19. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
20. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]